UK markets close in 7 hours 42 minutes
  • FTSE 100

    +26.98 (+0.38%)
  • FTSE 250

    +10.51 (+0.05%)
  • AIM

    -1.33 (-0.11%)

    -0.0029 (-0.24%)

    -0.0010 (-0.07%)

    -1,645.68 (-3.47%)
  • CMC Crypto 200

    -30.85 (-2.01%)
  • S&P 500

    +13.59 (+0.30%)
  • DOW

    -6.26 (-0.02%)

    -0.01 (-0.01%)

    +11.00 (+0.62%)
  • NIKKEI 225

    +96.27 (+0.34%)

    +89.96 (+0.35%)
  • DAX

    +95.09 (+0.61%)
  • CAC 40

    +67.24 (+1.01%)

ICL or NVZMY: Which Is the Better Value Stock Right Now?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Investors looking for stocks in the Chemical - Specialty sector might want to consider either Israel Chemicals (ICL) or Novozymes AS (NVZMY). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.

There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.

Israel Chemicals and Novozymes AS are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that ICL has an improving earnings outlook. But this is only part of the picture for value investors.

Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.

The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors.

ICL currently has a forward P/E ratio of 15, while NVZMY has a forward P/E of 42.78. We also note that ICL has a PEG ratio of 0.62. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. NVZMY currently has a PEG ratio of 8.56.

Another notable valuation metric for ICL is its P/B ratio of 2.06. The P/B ratio pits a stock's market value against its book value, which is defined as total assets minus total liabilities. For comparison, NVZMY has a P/B of 9.71.

These are just a few of the metrics contributing to ICL's Value grade of B and NVZMY's Value grade of D.

ICL stands above NVZMY thanks to its solid earnings outlook, and based on these valuation figures, we also feel that ICL is the superior value option right now.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ICL Group Ltd (ICL) : Free Stock Analysis Report
Novozymes AS (NVZMY) : Free Stock Analysis Report
To read this article on click here.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting